10-Q: Centessa Q3 Loss Widens Amid R&D Surge, Orexin Program Advances

Centessa Pharmaceuticals reported a widened net loss in Q3 2025 as increased R&D spending fueled progress in its OX2R agonist pipeline, including positive ORX750 and ORX142 clinical data.

Summary

• Net loss for the three months ended September 30, 2025, widened to $54.891 million, compared to $42.566 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss increased to $131.369 million, up from $124.428 million in the prior year period.
• Research and development expenses increased to $41.563 million for Q3 2025 (from $33.903 million in Q3 2024) and to $117.747 million for the nine months ended September 30, 2025 (from $89.370 million in 2024), primarily due to higher clinical study costs for ORX750 and ORX142, and IND-enabling costs for ORX489.
• Cash, cash equivalents, and investments totaled $349.0 million as of September 30, 2025, with an expected runway into mid-2027.
• The Phase 2a CRYSTAL-1 study for ORX750 showed statistically significant, clinically meaningful, and dose-dependent improvements in mean sleep latency (MWT), Epworth Sleepiness Scale (ESS) total score, and Weekly Cataplexy Rate (WCR) across Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) cohorts.
• ORX750 was generally well-tolerated, with common treatment-emergent adverse events (TEAEs) including pollakiuria (51%), insomnia (22%), dizziness (13%), and headache (11%).
• The Phase 1 first-in-human clinical study of ORX142 demonstrated rapid onset of action, differentiated pharmacokinetics, and statistically significant, dose-dependent improvements in MWT in acutely sleep-deprived healthy participants.
• ORX489, identified as the most potent OX2R agonist in preclinical studies, is currently in IND-enabling studies.
• The company recognized $15.0 million in license and other revenue during the nine months ended September 30, 2025, from an upfront payment related to an exclusive worldwide license of its LockBody technology platform to Genmab A/S.
• The discontinuation of the SerpinPC program in November 2024 resulted in a one-time charge of $31.5 million, which was fully extinguished as of September 30, 2025.
• Under its At-The-Market (ATM) Program, the company sold 372,538 ordinary shares for net proceeds of $6.1 million during the nine months ended September 30, 2025, contributing to a total of $36.6 million in net proceeds since the program's inception in 2023.
• The company will cease to be a smaller reporting company as of December 31, 2025, leading to increased disclosure requirements in the first fiscal quarter of 2026.

Sentiment

Score: 6

Explanation: While financial losses widened and cash burn was high, the positive clinical data for key pipeline assets (ORX750, ORX142) and a solid cash runway into mid-2027 provide a positive outlook for future development. The Genmab licensing deal also adds non-dilutive revenue and external validation for the LockBody platform. However, the significant cash usage and the need for future capital raises temper enthusiasm.

Positives

• ORX750 Phase 2a data demonstrated statistically significant, clinically meaningful, and dose-dependent improvements in key efficacy measures (MWT, ESS, WCR) for NT1, NT2, and IH patients, signaling a potentially wide therapeutic window.
• ORX750 exhibited a generally well-tolerated safety profile across all tested doses, with adverse events being transient and mild to moderate in severity.
• ORX142 Phase 1 study showed rapid onset of action, differentiated pharmacokinetics, and statistically significant, dose-dependent improvements in wakefulness, supporting its advancement to patient studies.
• The company's cash, cash equivalents, and investments of $349.0 million as of September 30, 2025, are projected to fund operations into mid-2027, providing a solid financial runway.
• A $15.0 million non-refundable upfront payment was received from Genmab A/S for an exclusive worldwide license to the LockBody technology platform, providing non-dilutive revenue and external validation.
• The One Big Beautiful Bill Act (OBBBA) enactment reduced the company's income tax liability for the current fiscal year by accelerating deferred tax asset recognition related to R&D expenditures.

Negatives

• Net loss widened to $54.891 million for Q3 2025, compared to $42.566 million for Q3 2024, and to $131.369 million for the nine months ended September 30, 2025, compared to $124.428 million for the prior year period.
• Cash and cash equivalents significantly decreased from $383.221 million at December 31, 2024, to $50.811 million at September 30, 2025.
• Net cash used in operating activities increased to $138.010 million for the nine months ended September 30, 2025, from $99.255 million in the prior year period.
• Net cash used in investing activities was $200.397 million for the nine months ended September 30, 2025, a significant outflow compared to a net inflow of $6.267 million in the prior year period.
• The accumulated deficit grew to $1,120.071 million as of September 30, 2025, from $988.702 million at December 31, 2024, indicating continued unprofitability.
• The discontinuation of the SerpinPC program in November 2024 resulted in a $31.5 million charge, reflecting a failed development asset and associated costs.
• The company will cease to be a smaller reporting company as of December 31, 2025, which will lead to increased disclosure requirements and potentially higher compliance costs in fiscal year 2026.

Risks

• The company may not successfully build a pipeline of commercially valuable product candidates using its asset-centric approach.
• A single or limited number of programs or product candidates may comprise a large proportion of the company's value, making it highly vulnerable to setbacks.
• The company has incurred net losses since inception and expects to continue incurring losses, with no guarantee of achieving or maintaining profitability.
• Substantial additional funds will be needed to advance product candidates, and there is no guarantee of sufficient future funding.
• The loan facility with Oxford Finance contains restrictive covenants, is subject to acceleration, and may adversely affect financial position or ability to raise additional capital.
• Product candidates are in various stages of development and may fail or suffer delays, materially affecting their commercial viability.
• The company may fail to differentiate its molecules (ORX750, ORX142, ORX489, LockBody) from other available treatment options.
• Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
• Substantial delays or challenges may be encountered in the initiation, conduct, or completion of clinical trials, and results are uncertain.
• The marketing approval process is expensive, time-consuming, and uncertain, potentially preventing commercialization.
• Inability to obtain U.S. or foreign regulatory approval would hinder development and commercialization.
• Reliance on third parties to conduct preclinical studies and clinical trials; unsatisfactory performance could substantially harm the business.
• Preclinical and clinical development is a long, expensive, and uncertain process, potentially leading to program termination.
• Manufacturing problems could result in delays or disruptions in development or commercialization.
• Business interruptions from geopolitical conflicts (e.g., Russia-Ukraine war, Middle East conflict, U.S.-China tensions) could adversely impact business activities and clinical trials.
• Inability to obtain and maintain sufficient patent and intellectual property protection, or if protection is not broad enough, competitors could commercialize similar products.
• Patent protection may be challenged or insufficient to provide a competitive advantage.
• Heavy dependence on licensed intellectual property; loss of rights could prevent development or commercialization.
• The company lacks the necessary expertise, personnel, and resources to successfully commercialize products independently.
• International operations expose the company to business, regulatory, legal, political, operational, financial, pricing, and reimbursement risks.
• Reduced reporting requirements as an emerging growth company and smaller reporting company may make ADSs less attractive to investors.
• Potential for material weaknesses in internal control systems over financial reporting, leading to reporting failures or misstatements.
• Uncertainty regarding Passive Foreign Investment Company (PFIC) status could have material adverse U.S. federal income tax consequences for U.S. holders.
• Inadequate funding for the FDA, SEC, and other government agencies could hinder their ability to review products or perform normal business functions.
• Adverse developments in the financial services industry (e.g., bank failures) could affect liquidity and operations.
• Future success depends on retaining key employees, consultants, and advisors, and attracting qualified personnel.
• Risk of employee misconduct or improper activities, including noncompliance with regulatory standards.
• Failure to comply with environmental, health, and safety laws could lead to fines or penalties.
• Cybersecurity incidents or data breaches could result in material disruption of product development programs.
• Stringent and changing privacy laws (e.g., GDPR, CCPA) could lead to government enforcement actions, private litigation, or harm to reputation.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• The price of the company's ADSs may be volatile, and investors could lose all or part of their investment.
• Sales of a substantial number of securities by shareholders in the public market could cause the ADS price to fall.
• An inactive trading market for ADSs could make it difficult for investors to sell their ADSs.
• If securities or industry analysts do not maintain research coverage or publish inaccurate/unfavorable research, the ADS price and trading volume could decline.
• Principal shareholders and management own a significant percentage of voting shares and can exert significant influence over matters subject to shareholder approval.
• Future sales and issuances of ADSs or rights to purchase ordinary shares could result in additional dilution of percentage ownership and cause the ADS price to fall.
• The company has broad discretion in the use of its cash resources and may not use them effectively.
• The company does not intend to pay dividends on its ordinary shares, so any returns will be limited to the value of its ordinary shares or ADSs.
• As a public company, the company may be at an increased risk of securities class action litigation, which is expensive and could divert management attention.
• The company incurs significant increased costs as a result of operating as a public company, and management must devote substantial time to compliance initiatives.
• Shareholder protections under the UK City Code on Takeovers and Mergers may not apply to the company.
• The rights of the company's shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.
• Certain capital structure decisions will require shareholder approval under English law, which may limit flexibility.
• Claims of U.S. civil liabilities may not be enforceable against the company.
• ADS holders' right to participate in any future rights offerings may be limited, which may cause dilution to their holdings.
• Patent terms may be inadequate to protect the company's competitive position for an adequate amount of time.
• Changes in patent law could diminish the value of patents in general, impairing the ability to protect product candidates.
• Intellectual property rights do not necessarily address all potential threats.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies.
• The company engages consultants employed by academic institutions in jurisdictions with inventorship laws that may mandate inventions reside in the employing institution, potentially limiting the company's rights.
• The company may be subject to claims by third parties asserting infringement, misappropriation, or other violations of their intellectual property rights, or claiming ownership of the company's intellectual property.

Future Outlook

The company expects its existing cash, cash equivalents, and investments of $349.0 million as of September 30, 2025, to fund operations into mid-2027. It anticipates incurring additional losses for the foreseeable future until significant product sales are generated, with R&D expenses expected to increase due to ongoing clinical trials and regulatory activities. The company plans for ORX750 Phase 2a study to inform dose selection for a registrational program in Q1 2026, and patient studies for ORX142 and clinical studies for ORX489 are also planned for Q1 2026. The company will cease to be a smaller reporting company as of December 31, 2025, leading to increased disclosure requirements and compliance costs in fiscal year 2026, though it will retain non-accelerated filer status for that year and has a one-year transition period for Sarbanes-Oxley Act Section 404(b) compliance.

Management Comments

• "We expect its existing cash, cash equivalents and investments as of September 30, 2025 of $349.0 million will be sufficient to fund its expected operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these unaudited interim consolidated financial statements."
• "We believe these data signal a potentially wide therapeutic window for ORX750 and provide strong mechanistic rationale supporting the potential to further enhance efficacy and dosing flexibility within ongoing and planned future dose-escalation cohorts in the Phase 2a study."
• "Based on the totality of the Phase 1 data, patient studies for undisclosed indications are planned for the first quarter of 2026."
• "ORX489 is our most potent OX2R agonist to date based on preclinical studies, and is in IND-enabling studies."
• "We expect to continue to incur significant expenses and operating losses for the foreseeable future in connection with ongoing development activities related to our pipeline programs as we advance the preclinical and clinical development of product candidates."

Industry Context

Centessa Pharmaceuticals operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industries, focusing on novel therapies for neurological disorders and immuno-oncology. Its OX2R agonist program targets conditions like narcolepsy and hypersomnolence, an area with increasing research and competitive activity. The discontinuation of the SerpinPC program highlights the intense competitive landscape in specific therapeutic areas, where new product approvals can quickly shift market dynamics. The licensing deal with Genmab for the LockBody platform reflects a trend of strategic collaborations to leverage specialized technologies and share development risks in complex fields like immuno-oncology. Legislative changes, such as the OBBBA and UK R&D tax incentive reforms, indicate a broader regulatory environment that impacts financial planning and operational costs for life science companies.

Corporate Governance

Legal Proceedings

• A proposed class-action lawsuit filed on September 28, 2022, against the company and certain current and former officers was dismissed with prejudice by the United States District Court for the Southern District of New York on August 27, 2024.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings (ATM program, shelf registration) and continued share price volatility. The influence of principal shareholders and management remains significant. ADS holders have limited voting rights and no expected dividends.
• Employees will see increased headcount in R&D, with share-based compensation as a retention tool. However, there is a risk of losing key personnel and potential for employee misconduct.
• Patients stand to benefit from the positive clinical trial results of ORX750 and ORX142, offering hope for new treatments for excessive daytime sleepiness, narcolepsy, and other neurological/neurodegenerative conditions.
• Creditors, particularly Oxford Finance, are secured by the company's assets under the Loan and Security Agreement, which includes restrictive covenants and potential for acceleration, impacting the company's financial flexibility.
• Partners, such as Genmab A/S, benefit from the licensing agreement for the LockBody technology platform, with potential for future milestone payments and royalties for Centessa.
• Regulatory bodies (FDA, EMA, MHRA) will continue to interact with the company regarding INDs, clinical trials, and future marketing approvals, with the company subject to their evolving regulations and potential for additional requirements.

Next Steps

• Continue dose escalation for ORX750 in the Phase 2a CRYSTAL-1 study with both once-daily and split-dose regimens.
• Utilize Phase 2a study results for ORX750 to enable dose selection for a registrational program planned for Q1 2026.
• Initiate patient studies for ORX142 in undisclosed neurological and neurodegenerative indications in Q1 2026.
• Advance ORX489, the most potent OX2R agonist, into clinical studies in Q1 2026, subject to IND clearance.
• Continue to identify and advance additional product candidates into clinical development.
• Manage and allocate cash judiciously to maintain the expected cash runway into mid-2027.
• Comply with increased disclosure requirements as the company ceases to be a smaller reporting company as of December 31, 2025.
• Prepare for compliance with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act after a one-year transition period.

Key Dates

Recommendation

The positive clinical data for ORX750 and ORX142 are significant catalysts, demonstrating progress in the core OX2R agonist pipeline and validating the company's asset-centric approach. The extended cash runway into mid-2027 provides a reasonable buffer for continued development. However, the company continues to incur substantial losses, and the need for future capital raises, coupled with the inherent risks of clinical development and commercialization in the highly competitive biotech sector, suggest a 'Hold' recommendation. Investors should monitor further clinical progress, regulatory milestones, and capital management closely.

Keywords

Biotechnology, Pharmaceuticals, Clinical-stage, OX2R agonist, Orexin, Narcolepsy, Hypersomnolence, LockBody, Immuno-oncology, Drug development, Clinical trials, R&D, SEC filing, 10-Q, Centessa Pharmaceuticals